2seventy bio, Inc. (NASDAQ:TSVT) Director Marcela V. Maus Sells 3,900 Shares

2seventy bio, Inc. (NASDAQ:TSVT) Director Marcela V. Maus sold 3,900 shares of 2seventy bio stock in a transaction on Monday, November 18th. The stock was sold at an average price of $3.38, for a total value of $13,182.00. Following the transaction, the director now directly owns 23,752 shares of the company’s stock, valued at $80,281.76. This trade represents a 14.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

2seventy bio Stock Down 3.4 %

TSVT opened at $3.11 on Thursday. The firm’s fifty day simple moving average is $4.64 and its 200 day simple moving average is $4.46. 2seventy bio, Inc. has a 12 month low of $1.53 and a 12 month high of $6.40.

Institutional Investors Weigh In On 2seventy bio

Several hedge funds have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. acquired a new stake in shares of 2seventy bio in the first quarter valued at approximately $2,031,000. Venator Management LLC raised its holdings in 2seventy bio by 49.2% in the 2nd quarter. Venator Management LLC now owns 485,000 shares of the company’s stock valued at $1,867,000 after acquiring an additional 160,000 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of 2seventy bio during the 1st quarter valued at $9,291,000. BBR Partners LLC lifted its position in shares of 2seventy bio by 66.7% during the 2nd quarter. BBR Partners LLC now owns 25,000 shares of the company’s stock valued at $96,000 after acquiring an additional 10,000 shares during the period. Finally, Nisa Investment Advisors LLC acquired a new stake in shares of 2seventy bio during the 2nd quarter worth $52,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley dropped their target price on shares of 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Monday, July 29th. One analyst has rated the stock with a sell rating, three have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, 2seventy bio has an average rating of “Moderate Buy” and an average price target of $9.00.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.